Ceregene Drug Fails in Parkinson’s Trial

Xconomy San Diego — 

Ceregene said its experimental gene therapy technique for Parkinson’s disease failed in a mid-stage clinical trial of 58 patients. The San Diego-based biotech company said its injectable treatment, CERE-120, didn’t offer a signficant improvement compared with a placebo. Ceregene’s chief scientist, Raymond Bartus, said in a statement he was “stunned” by the result, and will continue to analyze the findings to figure out why it turned negative. The company also has treatments in development for Alzheimer’s disease, Lou Gehrig’s disease, and eye conditions.

By posting a comment, you agree to our terms and conditions.

One response to “Ceregene Drug Fails in Parkinson’s Trial”

  1. this is dated 2008 and yet it is republished today. Can you please clarify whether the latest phase II cere-120 trial has also failed?